Abstract

To the Editor: We congratulate Rodrigues et al ( 1 Rodrigues G. Oberije C. Senan S. et al. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non–small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. Int J Radiat Oncol Biol Phys. 2015; 91: 133 Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar ) on their publication. The authors performed a multi-institutional retrospective analysis to explore whether intermediate dose escalation would lead to higher survival in stage III non-small cell lung cancer (NSCLC). They found a trend toward better survival in the intermediate dose group. Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non–Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched AnalysisInternational Journal of Radiation Oncology, Biology, PhysicsVol. 91Issue 1PreviewThe clinical benefits and risks of dose escalation (DE) for stage III non–small-cell lung cancer (NSCLC) remain uncertain despite the results from Radiation Therapy Oncology Group (RTOG) protocol 0617. There is significant heterogeneity of practice, with many clinicians prescribing intermediate dose levels between the 0617 study arms of 60 and 74 Gy. This study investigated whether this strategy is associated with any survival benefits/risks by analyzing a large multi-institutional database. Full-Text PDF In Reply to Cobben and JagerInternational Journal of Radiation Oncology, Biology, PhysicsVol. 92Issue 3PreviewTo the Editor: We thank Drs Cobben and Jager (1) for their interest in our analysis (2) examining the relationship between intermediate dose escalation and survival for stage III non-small cell lung cancer (NSCLC). The authors suggested that the time interval between positron emission tomography/computed tomography (PET/CT) and treatment may have influenced the survival results and have summarized the evidence linking PET/CT timing with disease progression. Full-Text PDF

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.